ME03393B - Anti-transglutaminazna 2 antitijela - Google Patents
Anti-transglutaminazna 2 antitijelaInfo
- Publication number
- ME03393B ME03393B MEP-2019-181A MEP2019181A ME03393B ME 03393 B ME03393 B ME 03393B ME P2019181 A MEP2019181 A ME P2019181A ME 03393 B ME03393 B ME 03393B
- Authority
- ME
- Montenegro
- Prior art keywords
- transglutaminase
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1209096.5A GB201209096D0 (en) | 2012-05-24 | 2012-05-24 | Compounds |
| PCT/GB2013/051373 WO2013175229A1 (en) | 2012-05-24 | 2013-05-24 | Anti -transglutaminase 2 antibodies |
| EP13730049.7A EP2855530B1 (en) | 2012-05-24 | 2013-05-24 | Anti-transglutaminase 2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03393B true ME03393B (me) | 2020-01-20 |
Family
ID=46546551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-181A ME03393B (me) | 2012-05-24 | 2013-05-24 | Anti-transglutaminazna 2 antitijela |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US10005846B2 (me) |
| EP (2) | EP2855530B1 (me) |
| JP (2) | JP6411998B2 (me) |
| KR (1) | KR102091223B1 (me) |
| CN (1) | CN104321346B (me) |
| AU (1) | AU2013265025B2 (me) |
| BR (1) | BR112014029089B1 (me) |
| CA (1) | CA2874488C (me) |
| CL (1) | CL2014003125A1 (me) |
| CO (1) | CO7151528A2 (me) |
| CY (2) | CY1121932T1 (me) |
| DK (2) | DK2855530T3 (me) |
| EA (1) | EA036810B1 (me) |
| EC (1) | ECSP14030942A (me) |
| ES (2) | ES2835383T3 (me) |
| GB (1) | GB201209096D0 (me) |
| HK (1) | HK1203974A1 (me) |
| HR (2) | HRP20191293T1 (me) |
| HU (2) | HUE052490T2 (me) |
| IL (1) | IL235369B (me) |
| IN (1) | IN2014MN02231A (me) |
| LT (2) | LT3521315T (me) |
| MA (1) | MA37670B1 (me) |
| ME (1) | ME03393B (me) |
| MX (1) | MX367517B (me) |
| MY (1) | MY185966A (me) |
| NZ (1) | NZ701424A (me) |
| PE (1) | PE20150346A1 (me) |
| PH (1) | PH12014502582A1 (me) |
| PL (2) | PL3521315T3 (me) |
| PT (2) | PT2855530T (me) |
| RS (2) | RS59135B1 (me) |
| SG (1) | SG11201407053YA (me) |
| SI (2) | SI2855530T1 (me) |
| TN (1) | TN2014000458A1 (me) |
| TR (1) | TR201906781T4 (me) |
| UA (1) | UA117657C2 (me) |
| WO (1) | WO2013175229A1 (me) |
| ZA (1) | ZA201408213B (me) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110055235A (zh) * | 2019-05-14 | 2019-07-26 | 深圳市亚辉龙生物科技股份有限公司 | 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法 |
| GB202115121D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115127D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202116665D0 (en) | 2021-11-18 | 2022-01-05 | UCB Biopharma SRL | Method for the treatment of a scleroderma disease |
| CA3238305A1 (en) | 2021-11-18 | 2023-05-25 | Timothy Scott JOHNSON | Method for the treatment of progressive chronic interstitial lung disease |
| GB202118010D0 (en) | 2021-12-13 | 2022-01-26 | UCB Biopharma SRL | Method for detecting and/or quantifying crosslinks formed by transglutaminases |
| CN116515786B (zh) * | 2023-04-26 | 2024-05-28 | 广东医科大学 | 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912120A (en) | 1986-03-14 | 1990-03-27 | Syntex (U.S.A.) Inc. | 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors |
| AU1268192A (en) | 1991-01-04 | 1992-08-17 | Board Of Regents, The University Of Texas System | Cloning and expression of tissue transglutaminases |
| WO1998004245A1 (en) | 1996-07-25 | 1998-02-05 | The Victoria University Of Manchester | Use of transglutaminase modulators to promote wound healing |
| GB0103024D0 (en) * | 2001-02-07 | 2001-03-21 | Rsr Ltd | Assay for Autoantibodies to tissue transglutaminase |
| WO2004069175A2 (en) | 2003-02-02 | 2004-08-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES |
| GB0314262D0 (en) | 2003-06-19 | 2003-07-23 | Univ Nottingham Trent | Novel compounds and methods of using the same |
| WO2006100679A2 (en) * | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| WO2008063760A2 (en) | 2006-10-18 | 2008-05-29 | The University Of Texas M.D. Anderson Cancer Center | Methods for treating cancer targeting transglutaminase |
| CN104530233B (zh) * | 2008-04-24 | 2018-01-30 | 株式会社遗传科技 | 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用 |
| AU2010225460B2 (en) | 2009-03-19 | 2014-05-01 | Queensland University Of Technology | Targets for growth factor signalling and methods of therapy |
| HU0900199D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis of gluten-induced autoimmune diseases |
| HU0900195D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis and treatment of gluten-induced autoimmune diseases |
| WO2011151395A2 (en) | 2010-06-02 | 2011-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
-
2012
- 2012-05-24 GB GBGB1209096.5A patent/GB201209096D0/en not_active Ceased
-
2013
- 2013-05-24 SG SG11201407053YA patent/SG11201407053YA/en unknown
- 2013-05-24 PL PL19163818T patent/PL3521315T3/pl unknown
- 2013-05-24 IN IN2231MUN2014 patent/IN2014MN02231A/en unknown
- 2013-05-24 RS RS20190909A patent/RS59135B1/sr unknown
- 2013-05-24 CA CA2874488A patent/CA2874488C/en active Active
- 2013-05-24 PT PT13730049T patent/PT2855530T/pt unknown
- 2013-05-24 AU AU2013265025A patent/AU2013265025B2/en active Active
- 2013-05-24 DK DK13730049.7T patent/DK2855530T3/da active
- 2013-05-24 PE PE2014002040A patent/PE20150346A1/es active IP Right Grant
- 2013-05-24 PT PT191638188T patent/PT3521315T/pt unknown
- 2013-05-24 EA EA201492162A patent/EA036810B1/ru not_active IP Right Cessation
- 2013-05-24 ES ES19163818T patent/ES2835383T3/es active Active
- 2013-05-24 SI SI201331487T patent/SI2855530T1/sl unknown
- 2013-05-24 PL PL13730049T patent/PL2855530T3/pl unknown
- 2013-05-24 UA UAA201413832A patent/UA117657C2/uk unknown
- 2013-05-24 MX MX2014014264A patent/MX367517B/es active IP Right Grant
- 2013-05-24 US US14/402,675 patent/US10005846B2/en active Active
- 2013-05-24 EP EP13730049.7A patent/EP2855530B1/en active Active
- 2013-05-24 DK DK19163818.8T patent/DK3521315T3/da active
- 2013-05-24 EP EP19163818.8A patent/EP3521315B1/en active Active
- 2013-05-24 MA MA37670A patent/MA37670B1/fr unknown
- 2013-05-24 ME MEP-2019-181A patent/ME03393B/me unknown
- 2013-05-24 SI SI201331811T patent/SI3521315T1/sl unknown
- 2013-05-24 TR TR2019/06781T patent/TR201906781T4/tr unknown
- 2013-05-24 WO PCT/GB2013/051373 patent/WO2013175229A1/en active Application Filing
- 2013-05-24 HU HUE19163818A patent/HUE052490T2/hu unknown
- 2013-05-24 ES ES13730049T patent/ES2728856T3/es active Active
- 2013-05-24 JP JP2015513275A patent/JP6411998B2/ja active Active
- 2013-05-24 LT LTEP19163818.8T patent/LT3521315T/lt unknown
- 2013-05-24 NZ NZ701424A patent/NZ701424A/en unknown
- 2013-05-24 HU HUE13730049A patent/HUE045539T2/hu unknown
- 2013-05-24 BR BR112014029089-0A patent/BR112014029089B1/pt active IP Right Grant
- 2013-05-24 RS RS20210033A patent/RS61286B1/sr unknown
- 2013-05-24 LT LTEP13730049.7T patent/LT2855530T/lt unknown
- 2013-05-24 MY MYPI2014003271A patent/MY185966A/en unknown
- 2013-05-24 CN CN201380026672.3A patent/CN104321346B/zh active Active
- 2013-05-24 KR KR1020147036419A patent/KR102091223B1/ko active IP Right Grant
-
2014
- 2014-10-28 IL IL235369A patent/IL235369B/en active IP Right Grant
- 2014-10-28 TN TN2014000458A patent/TN2014000458A1/fr unknown
- 2014-11-10 ZA ZA2014/08213A patent/ZA201408213B/en unknown
- 2014-11-18 CL CL2014003125A patent/CL2014003125A1/es unknown
- 2014-11-19 PH PH12014502582A patent/PH12014502582A1/en unknown
- 2014-12-12 EC ECIEPI201430942A patent/ECSP14030942A/es unknown
- 2014-12-23 CO CO14281628A patent/CO7151528A2/es unknown
-
2015
- 2015-05-11 HK HK15104401.8A patent/HK1203974A1/xx unknown
-
2018
- 2018-05-23 US US15/987,611 patent/US10961319B2/en active Active
- 2018-05-30 JP JP2018104139A patent/JP2018166510A/ja active Pending
-
2019
- 2019-07-18 HR HRP20191293TT patent/HRP20191293T1/hr unknown
- 2019-07-29 CY CY20191100807T patent/CY1121932T1/el unknown
-
2020
- 2020-12-14 US US17/121,541 patent/US11718686B2/en active Active
- 2020-12-23 HR HRP20202059TT patent/HRP20202059T1/hr unknown
-
2021
- 2021-01-11 CY CY20211100013T patent/CY1123926T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400016I1 (hu) | FCRN elleni antitestek | |
| IL264558A (en) | Anti–il–23p19 antibodies | |
| HK1204571A1 (en) | Protease-regulated antibodies | |
| HK1210192A1 (en) | Anti-siglec-15 antibodies siglec-15 | |
| ZA201408213B (en) | Anti-transglutaminase 2 antibodies | |
| HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
| PL2935330T3 (pl) | Przeciwciała przeciw notch3 | |
| EP2804876A4 (en) | NEW ANTIBODIES | |
| EP2927243A4 (en) | ANTI-VASOHIBIN ANTIBODY-2 | |
| IL235188A0 (en) | Antibodies against c-pdgf | |
| GB201209584D0 (en) | Modified antibodies |